Results from an early-stage trial demonstrate that using a combination of two precision medicines to target hard-to-treat cancers was safe and showed promise in a range of solid tumour types.
Genomics’ analysis engine utilises genetics to understand human biology as well as the safety and efficacy of potential new drugs. The engine consists of more than 100 billion data points.